Karska-Basta Izabella, Kubicka-Trzaska Agnieszka, Pogrzebielski Arkadiusz, Romanowska-Dixon Bozena
Klin Oczna. 2013;115(4):269-74.
To evaluate (ex vivo) the characteristic of fibrin clotting in patients with retinal vein occlusion.
Fifty nine patients with a history of retinal vein occlusion were enrolled in the study. The diagnosis of retinal vein occlusion was based on the typical fundus appearance, supplemented by digital photography, fluorescein angiography, and optical coherence tomography. The control group consisted of 59 subjects matched for age, sex, body mass index, medications, and cardiovascular risk factors. The ex vivo fibrin clots obtained from citrate plasma samples from all patients were used for the measurement of clot permeation, expressed as the permeability coefficient, Ks (Darcy constant). The turbidity of fibrin clot formation, reflected by the "lag phase" of the turbidity curve and maximum absorbance at plateau (deltaAb(max)), tissue-plasminogen activator (t-PA) - induced fibrinolysis characterized by maximum rates of increase in D-dimer levels (D-Drate) and maximum D-dimer concentrations (D-Dmax) were evaluated. The time required for 50% decrease in maximum clot absorption (t50%) was chosen as an additional marker of clot susceptibility to fibrinolysis.
Patients with retinal vein occlusion were characterized by the unfavourable plasma fibrin clot properties. Clot permeability was 30% lower, as compared to the controls (p < 0.0001), the "lag phase" was 11% shorter (p < 0.0001) indicating faster fibrin formation, and the deltaAb(max) was 19% higher (p < 0.0001), indicating thicker fibrin fibers. The D-Dmax indicating thrombotic mass available for fibrinolytic agents was 22% higher in the RVO group (p < 0.0001) and the t50% was 29% longer (p < 0.0001) compared with controls. Only the D-Drate was similar in both groups (p = 0.223). The differences remained statistically significant after adjustment for fibrinogen, glucose, and platelet count.
The results indicate that in patients with retinal vein occlusion, less porous plasma fibrin clots composed of thicker fibrils with the reduced permeability and susceptibility to lysis are found, as compared to controls. Plasma fibrinogen and C-reactive protein levels are recognized as the most important modulators of fibrin function. retinal vein occlusion, pathogenesis.
(体外)评估视网膜静脉阻塞患者纤维蛋白凝血的特征。
59例有视网膜静脉阻塞病史的患者纳入本研究。视网膜静脉阻塞的诊断基于典型的眼底表现,并辅以数码摄影、荧光素血管造影和光学相干断层扫描。对照组由59名年龄、性别、体重指数、用药情况和心血管危险因素相匹配的受试者组成。从所有患者的柠檬酸盐血浆样本中获得的体外纤维蛋白凝块用于测量凝块渗透,用渗透系数Ks(达西常数)表示。评估纤维蛋白凝块形成的浊度,以浊度曲线的“延迟期”和平台期最大吸光度(deltaAb(max))反映,组织型纤溶酶原激活剂(t-PA)诱导的纤维蛋白溶解,以D-二聚体水平的最大增加率(D-Drate)和最大D-二聚体浓度(D-Dmax)为特征。选择最大凝块吸收降低50%所需的时间(t50%)作为凝块对纤维蛋白溶解敏感性的额外标志物。
视网膜静脉阻塞患者的血浆纤维蛋白凝块特性不佳。与对照组相比,凝块通透性降低30%(p < 0.0001),“延迟期”缩短11%(p < 0.0001),表明纤维蛋白形成更快,deltaAb(max)升高19%(p < 0.0001),表明纤维蛋白纤维更粗。与对照组相比,RVO组中可用于纤溶药物的血栓形成物质D-Dmax高22%(p < 0.0001),t50%长29%(p < 0.0001)。两组之间只有D-Drate相似(p = 0.223)。在调整纤维蛋白原、葡萄糖和血小板计数后,差异仍具有统计学意义。
结果表明,与对照组相比,视网膜静脉阻塞患者的血浆纤维蛋白凝块孔隙较少,由较粗的纤维组成,通透性和溶解敏感性降低。血浆纤维蛋白原和C反应蛋白水平被认为是纤维蛋白功能最重要的调节因子。视网膜静脉阻塞,发病机制。